Ovarian Cancer Clinical Trials

Live data from ClinicalTrials.gov. Every recruiting trial, every published result. Updated daily.

796 Active Trials

25+ US States

2,140,529 Total Enrollment

Featured Recruiting Trials

Hand-picked trials across treatment categories. Each is actively recruiting participants right now.

NCT06890338 Recruiting

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Phase 2 · ADCs · 140 participants

NCT06315491 Recruiting

A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer

Phase 2 · Other · 40 participants

NCT05551208 Recruiting

Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi

Phase 2 · PARP Inhibitors · 42 participants

NCT05200559 Recruiting

T-regulatory Cell Depletion with E7777 Combined with Pembrolizumab in Recurrent or Metastatic Solid Tumors

Phase 1/2 · Immunotherapy · 70 participants

NCT05827523 Recruiting

Interval Cytoreductive Surgery With or Without HIPEC for Ovarian Cancer (FOCUS / KOV-HIPEC-04)

Phase 3 · Chemotherapy · 520 participants

NCT07285941 Recruiting

Efficacy and Safety of Distamab Vedotin Combined With Carboplatin for Advanced Ovarian Cancer in the First Line Treatment

Phase 2 · Immunotherapy · 20 participants

NCT06380660 Recruiting

Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors

Phase 1/2 · PARP Inhibitors · 298 participants

NCT06994195 Recruiting

A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer

Phase 3 · Chemotherapy · 384 participants

NCT06161025 Recruiting

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2/3 · Chemotherapy · 860 participants

NCT06560112 Recruiting

An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer

Phase 2 · Chemotherapy · 172 participants

NCT04789694 Recruiting

Prehabilitation in Gynaecological Cancer Patients

Phase 3 · Surgery · 64 participants

NCT06896981 Recruiting

Semaglutide in Women With Polycystic Ovary Syndrome and Obesity

Phase 2/3 · Other · 30 participants

NCT06954584 Recruiting

Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer

Phase 3 · PARP Inhibitors · 424 participants

NCT06943521 Recruiting

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

Phase 1/2 · Other · 27 participants

NCT05071937 Recruiting

ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

Phase 2 · PARP Inhibitors · 33 participants

Treatment Categories

Active trials organized by treatment approach.

333 Other

129 Chemotherapy

76 PARP Inhibitors

64 Immunotherapy

60 Surgery

59 Targeted Therapy

37 Hormone Therapy

20 ADCs

18 Cell Therapy

Trials by Phase

Clinical trials progress through phases to test safety and effectiveness. Here's the current distribution.

Early Phase 1

Phase 1

142

Phase 1/2

Phase 2

131

Phase 2/3

Phase 3

Phase 4

Trial Sites by State

The top 25 US states by number of trial sites. California leads with 671 sites across 796 active trials.

1 California 671

2 Illinois 542

3 Michigan 485

4 Ohio 466

5 Texas 400

6 New York 377

7 Florida 357

8 Pennsylvania 322

9 Wisconsin 320

10 Minnesota 289

11 Missouri 235

12 Washington 228

13 North Carolina 200

14 Colorado 189

15 New Jersey 166

16 Nevada 161

17 Virginia 160

18 Massachusetts 146

19 Oregon 129

20 Maryland 123

21 Iowa 122

22 Tennessee 111

23 South Carolina 105

24 Kentucky 103

25 Indiana 100

Need Help Finding the Right Trial?

A gynecologic oncologist can help you identify trials that match your diagnosis, stage, and treatment history.

Find a Specialist